Share this page:
Fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) of CASIRIVIMAB and IMDEVIMAB
Casirivimab and imdevimab to be administered together for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization.
Date Last Updated (Year-Month-Day)
Download Heathcare Providers Fact Sheet directly: https://www.fda.gov/media/143892/download
Download Patients, Parents, and Caregivers Fact Sheet directly: https://www.fda.gov/media/143893/download